KEVZARA (sarilumab), interleukin 6 receptor inhibitor
RHEUMATOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 12 2018
Reason for request
Substantial actual benefit but no clinical benefit demonstrated in the treatment of rheumatoid arthritis after failure of one or more disease-modifying treatments
- KEVZARA, administered subcutaneously, has Marketing Authorisation in the treatment of rheumatoid arthritis (RA) after failure of one or more disease-modifying treatments.
- It is a second-line treatment after failure of conventional disease-modifying treatments such as methotrexate (MTX) or a third-line treatment (failure of a biological medicinal product) or beyond (failure of multiple conventional disease-modifying and/or biological treatments).
- Its superiority has been demonstrated in monotherapy compared with adalimumab in second-line (inadequate response or intolerance to MTX) treatment.
» KEVZARA has not been compared to available third-line alternatives, in particular the other anti-IL6 (tocilizumab), abatacept or rituximab.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments